JPLA
MRNA icon

Joseph P. Lucia & Associates’s Moderna MRNA Stock Holding History

Joseph P. Lucia & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-598
Closed -$85K – 313
2022
Q2 		$85K Sell
598
-355
-37% -$50.7K 0.06% 153
2022
Q1 		$164K Buy
953
+25
+3% +$4.21K 0.1% 129
2021
Q4 		$236K Sell
928
-25
-3% -$7.31K 0.15% 113
2021
Q3 		$367K Sell
953
-80
-8% -$29.5K 0.22% 95
2021
Q2 		$243K Buy
1,033
+81
+9% +$14.5K 0.15% 114
2021
Q1 		$125K Sell
952
-538
-36% -$78K 0.06% 139
2020
Q4 		$156K Buy
+1,490
New +$151K 0.11% 123
2020
Q3 		– Sell
-1,490
Closed -$96K – 316
2020
Q2 		$96K Buy
+1,490
New +$81.6K 0.09% 139

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Joseph P. Lucia & Associates's MRNA Position: Q3 2022 in Review

Joseph P. Lucia & Associates sold out of Moderna (MRNA) in Q3 2022, closing a stake of 598 shares — an estimated $85K sold.

Joseph P. Lucia & Associates first reported a position in MRNA in Q2 2020 and held it in 8 quarters. The position peaked at $367K in Q3 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Joseph P. Lucia & Associates reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 598 Moderna shares in Q3 2022, an estimated $85K.
  • Joseph P. Lucia & Associates first reported a position in Moderna in Q2 2020 and held it in 8 quarters.
  • Joseph P. Lucia & Associates's Moderna position peaked at $367K in Q3 2021.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Joseph P. Lucia & Associates's 13F filing for Q3 2022, filed 28 Oct 2022.